Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer

Basit Öğe Kaydı
dc.authoridŞahin, Adem/0000-0002-3996-2931
dc.authoridTonbul, Hayrettin/0000-0001-5510-8973
dc.authoridTavukcuoglu, Ece/0000-0003-3344-468X
dc.authoridEsendagli, Gunes/0000-0003-4865-2377
dc.authoridCapan, Yilmaz/0000-0003-1234-9018
dc.authorwosidŞahin, Adem/IYT-0077-2023
dc.authorwosidTonbul, Hayrettin/AAR-6961-2020
dc.authorwosidÇapan, Yılmaz/AAM-5292-2021
dc.authorwosidTavukcuoglu, Ece/AAO-4229-2020
dc.authorwosidEsendagli, Gunes/Q-5136-2019
dc.contributor.authorTonbul, Hayrettin
dc.contributor.authorSahin, Adem
dc.contributor.authorTavukcuoglu, Ece
dc.contributor.authorEsendagli, Gunes
dc.contributor.authorCapan, Yilmaz
dc.date.accessioned2024-08-04T20:46:58Z
dc.date.available2024-08-04T20:46:58Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractDrug resistance is a major obstacle reducing the efficacy of cancer chemotherapy that decreases overall survival in breast cancer. P-glycoprotein (P-gp) inhibitors have potential to eliminate this problem whereas systemic usage of them such as elacridar is limited due to side effects and toxicity. This study aims to develop and evaluate paclitaxel and elacridar co-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles actively targeted to transferrin receptors to deliver anti-cancer drug and simultaneously overcome multi-drug resistance in breast cancer. In this study, PLGA nanoparticles were prepared by nanoprecipitation method and decorated with transferrin. Following characterization of the nanoparticles and drug release experiments, their efficacy was evaluated on breast cancer EMT6/AR1.0 cells which have high P-gp expression and resistance to paclitaxel. The average particle size and zeta potential of transferrin-decorated paclitaxel and elacridar co-loaded PLGA nanoparticles were 226.9 nm and - 3.9 mV, respectively. Their encapsulation efficiency was quite high (70-76%) and comparable for both paclitaxel and elacridar. Decoration with transferrin led to facilitated uptake of the nanoparticles by breast cancer cells and the combinatorial delivery of paclitaxel and elacridar through PLGA nanoparticles breached the resistance and enabled cytotoxicity. In conclusion, simultaneous and targeted delivery of nanoparticles co-loaded with P-gp inhibitors and anti-cancer drugs may be a promising approach for cancer therapy.en_US
dc.identifier.doi10.1016/j.jddst.2019.101380
dc.identifier.issn1773-2247
dc.identifier.issn2588-8943
dc.identifier.scopus2-s2.0-85075776772en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.jddst.2019.101380
dc.identifier.urihttps://hdl.handle.net/11616/99078
dc.identifier.volume54en_US
dc.identifier.wosWOS:000505159500020en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Drug Delivery Science and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNanoparticlesen_US
dc.subjectTransferrinen_US
dc.subjectPaclitaxelen_US
dc.subjectElacridaren_US
dc.subjectCanceren_US
dc.subjectMulti-drug resistanceen_US
dc.titleCombination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu